ERDOĞAN, T. Et Al. 2024. Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: a single-center experience for 4-year follow-up. ACTA NEUROLOGICA BELGICA , vol.124, no.4 , 1385-1391.

ERDOĞAN, T., CANSU, Ç., KOÇER, E. B., AKKAYA, S., & KÖKMEN, H., (2024). Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: a single-center experience for 4-year follow-up. ACTA NEUROLOGICA BELGICA , vol.124, no.4, 1385-1391.

ERDOĞAN, TUĞBA Et Al. "Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: a single-center experience for 4-year follow-up," ACTA NEUROLOGICA BELGICA , vol.124, no.4, 1385-1391, 2024

ERDOĞAN, TUĞBA Et Al. "Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: a single-center experience for 4-year follow-up." ACTA NEUROLOGICA BELGICA , vol.124, no.4, pp.1385-1391, 2024

ERDOĞAN, T. Et Al. (2024) . "Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: a single-center experience for 4-year follow-up." ACTA NEUROLOGICA BELGICA , vol.124, no.4, pp.1385-1391.

@article{article, author={TUĞBA ERDOĞAN Et Al. }, title={Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: a single-center experience for 4-year follow-up}, journal={ACTA NEUROLOGICA BELGICA}, year=2024, pages={1385-1391} }